Abstract
The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a modest proportion of patients. Thus most pediatric patients with GD will need treatment with radioactive iodine (RAI; 131I) or surgical thyroidectomy. When antithyroid drugs (ATDs) are prescribed, only methimazole (MMI) should be administered, as PTU is associated with an unacceptable risk of severe liver injury. If remission does not occur following ATD therapy, 131I or surgery should be contemplated. When 131I is administered, dosages should be greater than 150 μCi/g of thyroid tissue, with higher dosages needed for large glands. Considering that there will be low-level whole body radiation exposure associated with 131I, this treatment should be avoided in young children. When surgery is performed, near total or total thyroidectomy is the recommended procedure. Complications for thyroidectomy in children are considerably higher than in adults; thus an experienced thyroid surgeon is needed when children are operated on. Most importantly, the care of children with GD can be complicated and requires physicians with expertise in the area.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wilkins L. The diagnosis and treatment of endocrine disorders in children and adolescence. Springfield: Charles Thomas; 1965. p. 141–50.
Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol. 2008;158(6):823–7.
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.
Conference Proceeding: Hepatic toxicity following treatment for pediatric Graves’ disease meeting: October 28, 2008. Eunice Kennedy Shriver National Institute of Child Health and Human Development. http://bpca.nichd.nih.gov/outreach/index.cfm. 2009 [January 14, 2009]; Available from: http://bpca.nichd.nih.gov/outreach/index.cfm.
Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid. 2007;17(11):1103–7.
Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83(11):3767–76.
Fisher DA. Graves’ disease in children. Curr Ther Endocrinol Metab. 1994;5:71–4.
Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin N Am. 1998;27(1):109–26.
LeFranchi S, Mandel SH. Graves’ disease in the neonatal period and childhood. In: Braverman LE, Utiger RD, editors. Clinical text. Philadelphia: JB Lippincott; 1995. p. 1237–46.
Weetman AP. Grave’s disease 1835–2002. Horm Res. 2003;59 Suppl 1:114–8.
Weetman AP. Graves’ disease. N Engl J Med. 2000;343(17):1236–48.
Chapman EM. History of the discovery and early use of radioactive iodine. JAMA. 1983;250(15):2042–4.
Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–17.
Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves’ disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003;16(9):1249–55.
Talbot NB, Sobel EH, McArthur JW, Crawford JD. Functional endocrinology: from birth to adolescence. Cambridge: Harvard University Press; 1952. p. 1–51.
Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves’ disease. Endocrinol Metab Clin N Am. 1998;27(1):225–47.
Cooper DS. Which Anti-thyroid drug? Am J Med. 1986;80:1165–8.
Rivkees SA. 63 Years and 715 days to the “Boxed Warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol. 2010; 2010, 3 pages. Article ID 658267. doi:10.1155/2010/658267.
Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360(15):1574–5. Epub 2009/04/10.
Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009;2009:132041. Epub 2009/12/01.
Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.
Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2157–62.
Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995;88(9):973–6.
Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, et al. Treatment for childhood-onset Graves’ disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid. 2007;17(1):67–72.
Cassio A, Corrias A, Gualandi S, Tato L, Cesaretti G, Volta C, et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol. 2006;64(1):53–7.
Dotsch J, Rascher W, Dorr HG. Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs. 2003;5(2):95–102.
Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, et al. Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatr Endocrinol. 2000;13(7):879–85.
Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years. J Pediatr Endocrinol Metab. 1999;12(4):537–41.
Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, et al. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994;131(5):467–73.
Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Grave’s disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005;18(6):597–602.
Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2005;2, CD003420.
Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol. 2006;154(6):783–6.
Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983;98(1):26–9.
Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8(3):222–4.
Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves’ disease in children. Int J Pediatr Endocrinol. 2010;2010:176970. Epub 2010/03/13.
Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid. 2005;15(3):292–7.
Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, et al. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease. Clin Endocrinol. 2004;60(6):671–5.
Guma M, Olive A, Juan M, Salinas I. ANCA antibodies in Graves’ disease. Ann Rheum Dis. 2002;61(1):90–1.
Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005;38(1):93–103.
Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves’ disease. J Med Assoc Thai. 2002;85 Suppl 4:S1295–301.
Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, et al. Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves’ disease treated with propylthiouracil. Clin Nephrol. 2005;63(6):437–45.
Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol. 1998;10(1):45–50.
Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985;60(5):1019–24.
Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82(6):1719–26.
Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics. 2008;121(3):e481–8.
Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93(10):3817–26.
Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97(1):110–9. Epub 2011/10/28.
Weetman AP. Graves’ hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab. 2006;2:2–3.
Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990;70(3):675–9.
Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Investig. 1992;15(11):815–20.
Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease–prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50(1):127–32.
Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997;7(5):755–60.
Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves’ disease. Cochrane Database Syst Rev. 2008;3, CD006294.
Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987;64(6):1241–5.
Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000;85(10):3678–82.
Vitti P, Rago T, Chiovato L, Pallini S, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:69–375.
Kim WB, Chung HK, Lee HK, Kohn LD, Tahara K, Cho BY. Changes in epitopes for thyroid-stimulating antibodies in Graves’ disease sera during treatment of hyperthyroidism: therapeutic implications. J Clin Endocrinol Metab. 1997;82:1953–9.
Davies T, Roti E, Braverman LE, De Groot LJ. Thyroid controversy–stimulating antibodies. J Clin Endocrinol Metab. 1998;83:3777–85.
Rapoport B, Greenspan FS, Filetti P. Pepitone. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J Clin Endocrinol Metab. 1984;58:332–8.
Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin Endocrinol. 1986;25:151–6.
Bouma DJ, Kammer H, Greer MA. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. J Clin Endocrinol Metab. 1982;55:1138–42.
Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N Engl J Med. 1977;297:173–6.
Bing RF. Early remission in thyrotoxicosis produced by short coursed of treatment. Acta Endocrinol Suppl (Copenh). 1982;100:221–3.
Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–25. Epub 2002/11/06.
Wintergerst KA, Rogers ES, Foster MB. Hyperthyroidism presenting with hyperglycemia in an adolescent female. J Pediatr Endocrinol Metab. 2011;24(5–6):385–7. Epub 2011/08/10.
Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, et al. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012;13(8):652–5. Epub 2012/07/05.
Benavides VC, Rivkees SA. Myopathy associated with acute hypothyroidism following radioiodine therapy for Graves disease in an adolescent. Int J Pediatr Endocrinol. 2010;2010. Epub 2010/09/28.
van Veenendaal NR, Rivkees SA. Treatment of pediatric Graves’ disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011;96(10):3257–63. Epub 2011/08/19.
Williams ED. Biological effects of radiation on the thyroid. In: Braverman LE, Utiger RD, editors. The thyroid. Philadelphia: J.B. Lippincott Co.; 1986. p. 421–36.
Hertz BE, Schuller KE. Saul Hertz, MD (1905–1950): a pioneer in the use of radioactive iodine. Endocr Pract. 2010;16(4):713–5.
Sheline GE, McCormack KR, Galante M. Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine. J Clin Endocrinol Metab. 1962;22:8–17.
Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab. 1974;38:976–98.
Goolden AWG, Davey JB. The ablation of normal thyroid tissue with iodine-131. Br J Radiol. 1963;36:340–5.
Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–41.
Levy WM, Schumacher OP, Gupta M. Treatment of childhood Graves’ disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med. 1988;55:373–82.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7(2):247–51.
Graham GD, Burman KD. Radioiodine treatment of Graves’ disease. An assessment of its potential risks. Ann Intern Med. 1986;105:900–5.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Investig. 1995;25(3):186–93.
Becker DV, Hurly JR. Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med. 1971;1:442–60.
Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001;86(5):1865–7.
Refetoff S, Demeester-Mirkine N, Ermans AM, DeGroot LJ. Rapid control of thyrotoxicosis with combined 131I, antithyroid drugs and KI therapy. J Nucl Med Allied Sci. 1977;21:23–9.
Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983;57:250–3.
Rappaport R, Caplan R, De Groot LJ. Low-dose sodium iodine I 131 therapy in Graves disease. JAMA. 1973;224:1610–3.
Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med. 1989;87:70–3.
Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol. 1986;24:217–22.
McCullagh EP, Jelden GL, Rodriguez-Antunez A. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves’ disease. Oh State Med J. 1976;72:538–40.
Dobyns BM. Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J. 1975;58:94–7.
Safa AM. Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med. 1975;135:673–5.
Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.
Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volumes in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab. 1996;81:3257–60.
Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves’ disease. Clin Endocrinol. 1997;47:425–30.
Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611–7.
Crile G, Schumacher OP. Radioactive iodine treatment of Graves’ disease. Results in 32 children under 16 years of age. Am J Dis Child. 1965;110:501–4.
Hayek A, Chapman EM, Crawford JD. Long term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1970;283:949–53.
Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med. 1979;20:847–50.
Starr P, Jaffe HL, Oettinger L. Late results of 131I treatment of hyperthyroidism in 73 children and adolescents. J Nucl Med. 1964;5:81–9.
Starr P, Jaffe HL, Oettinger L. Later results of 131-I treatment of hyperthyroidism in 73 children and adolescence: 1967 follow-up. J Nucl Med. 1969;10:586–90.
Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D. Treatment of hyperthyroidism in children: analysis of forty-five patients. N Engl J Med. 1965;272:217–22.
Moll GW, Patel BR. Pediatric Graves’ disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J. 1997;90:1017–22.
Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1975;292:167–71.
Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4 Pt 1):745–9.
Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves’ disease in children. J Pediatr. 2002;141(1):99–103.
Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? J Clin Endocrinol Metab. 2003;88(3):975–7.
Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.
De Groot LJ, Gorman CA, Pinchera A, Bartalena L, Marcocci C, Wiersinga WM, et al. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1995;80:339–40.
Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid. 1997;7(2):241–5.
Saxena KM, Crawford JD, Talbot NB. Childhood thyrotoxicosis: a long term perspective. Br Med J. 1964;2:1153–8.
Lafranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann. 1992;21(1):29. 32–9.
Barnes HV, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolescence. J Pediatr. 1977;91:313–20.
Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery. 1996;120(6):1020–4. discussion 4–5.
Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment. Trends in Endocrinology & Metabolism. 2002;13(7):280–7.
Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med. 1976;17:460–4.
Boice Jr JD. Radiation-induced thyroid cancer–what’s new? J Natl Cancer Inst. 2005;97(10):703–5.
Boice Jr JD. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006;295(9):1060–2.
Ron E, Lubin J, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259–77.
Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys. 1968;15:219–28.
Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365(9476):2014–23.
Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006;91(6):2159–64.
Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712–8.
Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294(1):71–80.
Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res. 1990;50:2283–9.
Holm LE, Hall P, Wiklund K, Lundell G, Berq G, Cederquist E, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83:1072–7.
Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2190–6.
Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347–55.
Read Jr CH, Tansey MJ, Menda Y. A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89(9):4229–33.
Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics. 2000;20(2):533–46.
Toohey RE, Stabin MG, editors. Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99-1064, 1999. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium; 1996; Gatlinburg, TN.
Health risks from exposure to low levels of ionizing radiation: BEIR VII – Phase 2. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation NRC, editor. Washington, DC: National Academies Press; 2006.
Ching T, Warden MJ, Fefferman RA. Thyroid surgery in children and teenagers. Arch Otolaryngol. 1977;103:544–6.
Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD. Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child. 1981;135(2):112–7.
Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol. 1996;134:710–5.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Investig. 1996;26(1):59–63.
Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93(8):3058–65.
Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R. Effect of patient age on surgical outcomes for Graves’ disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol. 2013;2013(1):1. Epub 2013/01/29.
Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15(6):569–74.
Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin N Am. 2004;84(3):849–74.
Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, et al. Surgery for Graves’ disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg. 2000;24(11):1303–11.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–30.
Breuer C, Tuggle C, Solomon D, Sosa JA. Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:79–85. Epub 2012/11/15.
Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, et al. Surgical management of pediatric Graves’ disease: an effective definitive treatment. Pediatr Surg Int. 2012;28(6):609–14. Epub 2012/05/01.
Read Jr CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89(9):4229–33.
Conflicts of Interest
The authors have no potential conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rivkees, S.A. (2015). Graves’ Disease in Childhood. In: Bahn, R. (eds) Graves' Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2534-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2534-6_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2533-9
Online ISBN: 978-1-4939-2534-6
eBook Packages: MedicineMedicine (R0)